Dr. Hur received his bachelor degree from Columbia University, his MD and MPH degrees from Johns Hopkins University and completed his Internal Medicine residency at the Johns Hopkins Hospital. He subsequently completed his fellowship in Gastroenterology at the Beth Israel Deaconess Medical Center and then joined the faculty of the MGH Gastrointestinal Unit in 2002.

Dr. Hur's areas of clinical areas of interests include: gastroesophageal reflux disease (GERD), Barrett's esophagus, esophageal adenocarcinoma as well as gastrointestinal cancer screening. His research interest lies in outcomes research, specifically technology assessment with a focus on decision analysis and disease modeling, and the application of these methodologies to the management of cancers and pre-malignant states (e.g. dysplasia) in the gastrointestinal tract. This management includes the identification of clinical predictors, diagnostic algorithms, and the optimization of treatment.

Some of the specific projects that he has been involved with include a disease model of Barrett's Esophagus and Esophageal Cancer, an analysis of the impact of the implementation of Virtual Colonoscopies for colorectal cancer (CRC) screening and the possible role for chemoprevention in cancer care.

• Analysis of barriers to and patients' preferences for CT colonography for colorectal cancer screening in a nonadherent urban population.
• Patient preferences for the chemoprevention of colorectal cancer
• Cost-effectiveness of prophylactic surgery for duodenal cancer in familial adenomatous polyposis
• Consensus Guidelines in the Management of Branch Duct Intraductal Papillary Mucinous Neoplasm: A Cost-Effectiveness Analysis
• Development of an empirically calibrated model of gastric cancer in two high-risk countries

• The Effectiveness and Potential Impact of Computed Tomographic Colonography (Virtual Colonoscopy) on Colorectal Cancer Screening
• The Development and Analysis of a Population simulation disease model of Gastroesophageal Reflux Disease (GERD), Barrett’s Esophagus (BE) and Esophageal Adencarcinoma (EAC)
• Chemoprevention for the Prevention and Management of Gastrointestinal (GI) Cancers
• The Development of Prediction Rules to Improve Endoscopic Utilization for GERD/BE/EAC
• Shared Decision Making Related to BE/EAC and other GI Malignancy’s Management